https://ir.ymlib.yonsei.ac.kr/handle/22282913/168952 2026-07-18T09:46:31Z 2026-07-18T09:46:31Z Choi, Kyung Hwa Park, Juhee Yoon, Hyemee Park, Keunwan Hur, Cheolgoo Kim, Seok-Mo Park, Ki Cheong Lim, Jin Hong https://ir.ymlib.yonsei.ac.kr/handle/22282913/212973 2026-07-14T07:39:03Z 2026-12-01T00:00:00Z

Title: PPS03 triggers cancer-selective necroptosis in hepatocellular carcinoma via macropinocytosis-dependent ROS overload Authors: Choi, Kyung Hwa; Park, Juhee; Yoon, Hyemee; Park, Keunwan; Hur, Cheolgoo; Kim, Seok-Mo; Park, Ki Cheong; Lim, Jin Hong Abstract: Hepatocellular carcinoma (HCC) may be curable when detected and at an early stage. However, recurrence and metastatic progression occur frequently following therapeutic intervention, leading to treatment-refractory disease. Such refractory HCCs are resistant to systemic therapies, facilitating metastatic dissemination and disease relapse, highlighting the need for alternative therapeutic strategies. To address the limited efficacy of available systemic therapies, we developed a new polyaspartic acid (PASP) based polymer-metal complex, PPS03, with well-defined physicochemical properties, including nanoscale size distribution and stable metal incorporation. We showed that PPS03 induced cancer-selective necroptosis through preferential macropinocytic uptake in patient-derived metastatic HCC models. Specifically, PPS03 promoted necroptotic cell death by stimulating an accumulation of the mitochondrial reactive oxygen species (ROS) via selective intratumoral elevation of hydrogen peroxide (H2O2). Mechanistically, PPS03 exploited differential macropinocytic activity, which is high in tumor cells but very low in normal hepatocytes. This activity enabled selective uptake of PPS03-bound selenomethionine and ferrous iron, amplifying H2O2-mediated mitochondrial ROS production within cancer cells. Consistent with this selectivity, PPS03 exhibited minimal cytotoxicity in normal THLE-2 hepatocytes, while it strongly suppressed the viability of HCC cells. Notably, in patient-derived cisplatin-resistant metastatic HCC models, PPS03 significantly inhibited tumor growth both in vitro and in vivo whereas cisplatin showed no significant efficacy. Furthermore, PPS03 reduced stem-like tumor features, as evidenced by decreased sphere formation and reduced CD133 expression, likely reflecting preferential elimination of stem-like tumor cells. Collectively, these findings present PPS03 as a polymer-metal complex that selectively induces necroptosis in refractory HCC with minimal off-target toxicity, providing a potential therapeutic strategy to address drug resistance in advanced disease.

2026-12-01T00:00:00Z Wang, Qingyang Choi, Seoyeon Heo, Woong Kim, Min Woo Park, Sunyoung Park, Seong Jun Shin, Joonchul Hyun, Kyung-A Kim, Jungho Lim, Chae Seung Jung, Hyo-Il https://ir.ymlib.yonsei.ac.kr/handle/22282913/212974 2026-07-14T07:39:04Z 2026-11-01T00:00:00Z

Title: Electrochemical-sensor-assisted lab-in-a-cartridge (EC-LIC) for on-site detection of SARS-CoV-2 with a self-contained heating system Authors: Wang, Qingyang; Choi, Seoyeon; Heo, Woong; Kim, Min Woo; Park, Sunyoung; Park, Seong Jun; Shin, Joonchul; Hyun, Kyung-A; Kim, Jungho; Lim, Chae Seung; Jung, Hyo-Il Abstract: Rapid and accurate detection of respiratory viruses is essential for controlling disease transmission and enabling effective public health responses, particularly in resource-limited settings. In this study, we present an electrochemical-sensor-assisted lab-in-a-cartridge (EC-LIC) platform for on-site detection of SARS-CoV-2 featuring a self-contained chemical heating system. The device incorporates rotational and gravity-driven fluid handling along with exothermic heating using calcium oxide and a flameless ration heater to generate controlled temperature gradients. Coupled with a CRISPR-Cas13a-based electrochemical sensor, the system enables direct detection of the SARS-CoV-2 N gene without nucleic acid amplification, achieving high sensitivity and specificity. Integrated with a handheld electrochemical reader, the EC-LIC operates as a fully automated sample-to-answer system, completing the assay within 40 min over a wide dynamic range from 1.0 & times; 10 degrees to 1.0 & times; 105 fg/mL with a limit of detection as low as 1.21 & times; 10- 1 fg/mL. Clinical validation using samples from 102 individuals (60 positive and 42 negative) demonstrated a sensitivity of 98% and a specificity of 90%. These results establish the EC-LIC as a robust nucleic acid detection platform for rapid clinical screening and early epidemic response.

2026-11-01T00:00:00Z Kim, Doyoun Lee, Hye Sun Lee, Jae-Hoon Kang, Jeonghyun https://ir.ymlib.yonsei.ac.kr/handle/22282913/212975 2026-07-14T07:39:04Z 2026-10-01T00:00:00Z

Title: Intermuscular adipose tissue as a prognostic biomarker for overall survival in colorectal cancer Authors: Kim, Doyoun; Lee, Hye Sun; Lee, Jae-Hoon; Kang, Jeonghyun Abstract: Background: The prognostic value of intermuscular adipose tissue (IMAT) in patients with colorectal cancer (CRC) depends on both the anatomical site selected for CT imaging and the analytical technique employed. This study assessed the clinical significance of IMAT-related parameters in patients with CRC. Methods: This retrospective cohort study included stage I-III CRC patients who underwent surgery at a single tertiary center between 2005 and 2014. CT scans at the L3 level measured skeletal muscle and IMAT area and radiodensity. Sex-specific cutoffs for IMAT index (IMAI: IMAT area/height2) and IMAT radiodensity (IMAD) were defined using the X-tile program. Patients were further categorized into IMAT-combined groups (G1, G2, G3, and G4) according to the cutoff values of IMAI and IMAD. Survival was analyzed using Kaplan-Meier curves, log-rank tests, and Cox regression. Prognostic accuracy was evaluated with the concordance index (C-index). Results: Among 1080 patients (59.4% male), lower IMAI and IMAD correlated with better overall survival (OS). IMAT-combined groups were independent prognostic factors, with G2-G4 showing significantly better OS than G1. Patients were reclassified into two groups (G1 vs. G2-G4), termed the "IMAT model." The C-index demonstrated that incorporating the IMAT model yielded superior predictive performance compared to SMI alone (0.629 vs. 0.579; bootstrap mean difference = 0.050, 95% CI: 0.021-0.091) and SMD alone (0.617 vs. 0.590; bootstrap mean difference = 0.027, 95% CI: 0.009-0.052). Conclusions: The IMAT model is a significant independent prognostic factor for patients with CRC. Its use may enhance prognostic accuracy and support personalized treatment planning.

2026-10-01T00:00:00Z Yoon, Tae-in Kim, Ah Yoon Lee, Su Min Kim, Jisun Chung, Il Yong Ko, Beom Seok Kim, Hee Jeong Lee, Jong Won Son, Byung Ho Nam, Seok Jin Kim, Seok Won Lee, Jeong Eon Yu, Jonghan Park, Woong Ki Yi, On Vox Ryu, Jai Min Lee, Sae Byul https://ir.ymlib.yonsei.ac.kr/handle/22282913/212422 2026-06-09T06:45:16Z 2026-08-01T00:00:00Z

Title: Effect of adjuvant endocrine therapy on recurrence and contralateral breast cancer in HR-positive DCIS after mastectomy Authors: Yoon, Tae-in; Kim, Ah Yoon; Lee, Su Min; Kim, Jisun; Chung, Il Yong; Ko, Beom Seok; Kim, Hee Jeong; Lee, Jong Won; Son, Byung Ho; Nam, Seok Jin; Kim, Seok Won; Lee, Jeong Eon; Yu, Jonghan; Park, Woong Ki; Yi, On Vox; Ryu, Jai Min; Lee, Sae Byul Abstract: Background: The clinical benefits of adjuvant endocrine therapy for patients with hormone receptor (HR)-positive ductal carcinoma in situ (DCIS) undergoing mastectomy remain controversial. While endocrine therapy is known to reduce recurrence after breast-conserving surgery, its role post-mastectomy is unclear. We aimed to assess the impact of adjuvant endocrine therapy on recurrence and contralateral breast cancer (CBC) in patients with HRpositive DCIS treated with mastectomy. Methods: In this retrospective multicenter cohort study, we included patients with HR-positive, pure DCIS who underwent mastectomy between 2003 and 2018 across three cancer centers in South Korea. Patients were stratified based on receipt of adjuvant endocrine therapy (ETx). Logistic regression and Cox proportional hazards models were used to evaluate associations between ETx and recurrence or CBC. Annual hazard rates were estimated using kernel-smoothed functions. Results: Of 1,186 eligible patients, 599 (50.5 %) received endocrine therapy. Median follow-up was 86.3 months. The recurrence rate was significantly lower in the ETx group compared to no-ETx (7.0 % vs. 11.7 %; OR, 0.57; p = 0.005). Locoregional recurrence was also lower (2.5 % vs. 4.8 %; OR, 0.51; p = 0.04). CBC occurred in 5.3 % overall, with a non-significant reduction in the ETx group (4.2 % vs. 6.5 %; OR, 0.63; p = 0.08). In multivariable Cox models, ETx was associated with reduced recurrence (HR, 0.53; p = 0.01) and CBC (HR, 0.53; p = 0.04). Risk reduction persisted beyond 10 years. Conclusion: Adjuvant endocrine therapy was associated with significant reductions in recurrence and CBC risk after mastectomy for HR-positive DCIS, supporting selective use based on individual risk assessment.

2026-08-01T00:00:00Z